Gentian Diagnostics AS
GENT.OL
Get informed when a big investor buys or sells
+ FollowMarket Cap$602.89M
Close$
Share Statistics
| Market cap | $602.89 Million |
|---|---|
| Enterprise Value | $540.35 Million |
| Dividend Yield | $0.60 (1.54%) |
| Earnings per Share | $0.86 |
| Beta | 0.48 |
| Outstanding Shares | 15,449,456 |
Return
| Return on Equity | -4.60% |
|---|---|
| Return on Assets | -3.76% |
| Return on Invested Capital | 0.17% |
Valuation & Multiples
| P/E Ratio | -70.91 |
|---|---|
| PEG | 21.8 |
| Price to Sales | 3.55 |
| Price to Book Ratio | 3.55 |
| Enterprise Value to Revenue | 2.97 |
| Enterprise Value to EBIT | 1627.57 |
| Enterprise Value to Net Income | -65 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.09 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 9, 2026
EPS Estimate
$-0.32
Average shareholder expectationRevenue Estimate
$24.20 M
Average shareholder expectationNext Earnings Call
Expected Date
October 20, 2026
EPS Estimate
$-0.32
Average shareholder expectationRevenue Estimate
$24.20 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Gentian Diagnostics AS
64 employees
CEO: Matti Heinonen Gentian Diagnostics ASA develops, manufactures, and sells biochemical reagents for use in medical diagnostics and research in the United States, Asia, and Europe. It offers in-vitro diagnostic reagents for clinical chemistry analyzers, s...